Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash flows from operating activities
Net loss	$ (82,764)	$ (114,780)	$ (74,356)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash other income/expense, net	(40)	362	(1,371)
Non-cash interest income	22	45
Non-cash interest expense	519	(104)
Depreciation and amortization expense	396	510	432
Amortization of right-of-use assets	374
Stock-based compensation	9,748	5,154	5,732
In-process research and development in connection with acquisition		32,048
Deferred income taxes			1,410
Other, net	48	14	131
Changes in operating assets and liabilities:
(Increase)/decrease in long-term receivables	50	(3)	(5)
(Increase)/decrease in accounts receivable, net and other receivables and prepaid expenses	2,582	1,139	(223)
Increase in inventory	(682)
Increase/(decrease) in accounts payable	1,310	(2,969)	2,585
Increase/(decrease) in accrued expenses and other liabilities	(3,209)	5,742	(3,778)
Increase/(decrease) in other non-current liabilities	(172)	61	96
Increase/(decrease) in income tax liabilities	(74)	58	(1)
Net cash used in operating activities	(71,892)	(72,723)	(69,348)
Cash flows from investing activities
Purchases of plant and equipment and intangible assets	(61)	(229)	(1,173)
Purchases of term deposits		(115)	(30)
Changes in restricted cash	392
Proceeds from sale of property, plant and equipment			2
Transaction costs related to Zavante acquisition, net of cash acquired		(4,260)	50,950
Net cash provided by (used in) investing activities	331	(4,604)	49,749
Cash flows from financing activities
Proceeds from equity offerings and warrants	20,138	50,000	80,000
Proceeds from at-the-market facility	27,944	24,219
Proceeds from long-term debt, net of issuance costs	9,980	23,545	228
Proceeds from exercise of stock options			83
Proceeds from employee share purchase plan	372
Equity transaction costs	(2,359)	(4,841)	(8,092)
Net cash provided by financing activities	56,075	92,923	72,219
Effects of foreign currency translation on cash and cash equivalents	(106)	(362)	1,371
Net increase/(decrease) in cash, cash equivalents and restricted cash	(15,592)	15,234	53,991
Cash, cash equivalents, and restricted cash at beginning of year	102,003	86,769	32,778
Cash, cash equivalents and restricted cash at end of year	86,411	102,003	86,769
Supplemental disclosure of cash flow information:
Interest paid	(2,560)	(7)	(1)
Taxes paid	(11)	(4)	(5)
Equity transaction costs included in accounts payable and accrued expenses	$ 555	$ 120	$ 28